Moderna Settles COVID Vaccine Patent Dispute for Up to $2.25 Billion
In a major development for the biotech industry and global health sector, Moderna has agreed to settle a long running COVID Vaccine patent dispute for up to $2.25 billion. The agreement closes a key legal battle linked to its blockbuster mRNA based COVID 19 vaccine, widely known as Spikevax.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
